Table 2.

High levels of Annexin-A2 (ANXA2) in serum as a potential biomarker for cancers

Tumor type	N	p value	Results	Reference
Hepatocellular carcinoma	70	<  0.001	Patients (n = 50, median, 69.6 ng/ml) Healthy individuals (n = 20, median, 9.5 ng/ml)	[25]
Hepatocellular carcinoma (early stage)	70	<  0.01	Patients (n = 50, median, 130 ng/ml) Healthy individuals (n = 20, median, 17 ng/ml)	[26]
Gastric cancer	93	<  0.001	Patients (n = 63, median, 211.0 ng/ml) Healthy individuals (n = 30, median, 120.5 ng/ml)	[27]
Lung cancer	85	<  0.01	Patients (n = 42) Healthy individuals (n = 43)	[28]
Oral squamous cell carcinoma	284	<  0.01	Patients (n = 126, median, 27.1 ng/ml) Healthy individuals (n = 158, median, 15 ng/ml)	[29]

Method: enzyme-linked immunosorbent assay; N, total number of patients